课题基金 / 基金详情

A multiple antigen lipophilic adjuvant carrier (MALAC) system

A multiple antigen lipophilic adjuvant carrier (MALAC) system
多抗原亲脂性佐剂载体(MALAC)系统
批准号:
nhmrc : 252733
负责人:
Prof Istvan Toth
金额:
$9.44万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2003
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2003-01-01 至 2003-12-31

项目摘要

项目成果

Prof Istvan Toth的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We have developed a Multiple-Antigen-Lipophilic-Adjuvant-Carrier (MALAC) system, based on the incorporation of lipoamino acids into a poly-functional core that provides an excellent means for enhancing the antigenicity of a potential peptide vaccine. A system is used for generating antibodies without the use of any conventional adjuvant. The system comprises two or more different antigens and one or more lipid anchor. The key of this system is a novel carrier construct, which is non-toxic and non-immunogenic. The system contains variables, which allow optimising its structural configuration. A small library of poly-functional MALAC system will be synthesised in a controlled step-by-step way combining solution or solid phase techniques, where the exact chemical structure (and the order of the different immunological peptide sequences) of the construct is pre-determined. The antigenicity and the protection against disease will be compared with antigenicity and protection generated using conventional vaccine carriers. We also aim to exploit the particulate-forming properties of the lipo-peptide amphiphiles, to form micro-particulate oral antigens, exploiting the phenomenon of particulate uptake from the GI tract by the GALT or other intestinal sites. The MALAC constructs will be administered orally followed by the measurement of the serum IgG. Vaccination via the oral route is highly desirable, since it can overcome many of the disadvantages inherent in administration by injection - e.g. poor patient acceptability, requirement of skilled medical personnel, risk of HIV and other blood-born diseases, restricted availability and sometimes, stimulation of the wrong type of immunity. Development of vaccines for oral administration make them much more widely available, permitting self-administration and improving the operation of Public-Health vaccination programs, particularly in developing countries.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the myometrial transition at term and preterm labour to guide tocolysis
  • 批准号:
    nhmrc : 1126795
  • 项目类别:
    Project Grants
  • 资助金额:
    $55.22万
  • 财政年份:
    2017
  • 负责人:
    Prof Istvan Toth
  • 依托单位:
Development of a multicomponent delivery system for oligonucleotides
  • 批准号:
    DP130100952
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $26.28万
  • 财政年份:
    2013
  • 负责人:
    Prof Istvan Toth
  • 依托单位:
Liposaccharide based peptide and vaccine delivery systems: improving the bioavailability and immunogenicity of Luteinizing Hormone-Releasing Hormone
  • 批准号:
    DP110100212
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $74.07万
  • 财政年份:
    2011
  • 负责人:
    Prof Istvan Toth
  • 依托单位:
Lipid and Carbohydrate Based Systems to Target and Deliver Peptide Drug Candidates to Specific Cells
  • 批准号:
    DP1092829
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $52.26万
  • 财政年份:
    2010
  • 负责人:
    Prof Istvan Toth
  • 依托单位:
国内基金
海外基金
COSMC/Tn antigen/mTOR 轴调控胃癌细胞转移的分子机制 研究
  • 批准号:
    2024JJ9400
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    赵娟霞
  • 依托单位:
T细胞识别的鳞状细胞癌1型抗原增强干扰素-α抗丙型肝炎病毒作用的研究
  • 批准号:
    81170386
  • 项目类别:
    面上项目
  • 资助金额:
    45.0万元
  • 批准年份:
    2011
  • 负责人:
    赵鸿
  • 依托单位:
新的膀胱癌特异基因UCA1在膀胱癌高表达的分子机理
  • 批准号:
    30801325
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2008
  • 负责人:
    张争
  • 依托单位:
基于短寿蛋白肿瘤疫苗诱导的抗瘤作用及其机制的研究
  • 批准号:
    30771999
  • 项目类别:
    面上项目
  • 资助金额:
    33.0万元
  • 批准年份:
    2007
  • 负责人:
    王立新
  • 依托单位: